Quick Read – Pfizer trades at 9x forward earnings, pays a 6.6% dividend backed by real free cash flow, and eleven directors simultaneously bought shares in April. – Eli Lilly’s entire growth story rides two drugs while investors pay 41x trailing earnings, with realized prices…
ready down 13% in Q1 2026. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn’t make the cut. Grab the names FREE today
Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here’s what you should actually be watching. The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price Strip away the narrative and Lilly is a concentration trade dressed up as a growth story.
Mounjaro and Zepbound drive the entire P&L, with Mounjaro revenue of $8.66 billion (+125%) and Zepbound at $4.16 billion U.S. (+80%) doing the heavy lifting in Q1. Management itself flags “dependence on relatively few products for significant revenue” as a top risk, and realized prices already declined 13% in Q1 2026 as Mounjaro got folded into China’s national reimbursement list. You are paying 41x trailing earnings and 31x forward for that risk, on a stock that sits at $1,144.68 after a 48.98% one-year rip.